Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136255 | 0.77 | OPRM1 (0.46) | OPRM1OPRD1OPRK1 | |
| SCHEMBL4141367 | 0.73 | ALDH1A1 (0.40) | OPRM1MEN1KMT2AALDH1A1 | |
| SCHEMBL6928584 | 0.73 | ATM (0.55) | OPRM1OPRD1OPRK1OPRL1KMT2A | |
| SCHEMBL7244002 | 0.72 | CHRNB2 (0.36) | — | |
| SCHEMBL11097655 | 0.71 | CCR5 (0.46) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| Diphenamide SCHEMBL1258108 | 0.70 | ALDH1A1 (0.53) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| Diphenamide SCHEMBL572567 | 0.70 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| Diphenamide SCHEMBL39339 | 0.69 | ALDH1A1 (0.55) | OPRM1OPRL1MEN1KMT2ACRHBP | |
| Diphenamide SCHEMBL9202269 | 0.69 | ALDH1A1 (0.55) | OPRM1OPRL1MEN1KMT2ACRHBP | |
| Diphenamide SCHEMBL6910614 | 0.69 | ALDH1A1 (0.55) | OPRM1OPRL1MEN1KMT2ACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | claimed |
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1934184-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039884-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | OPRM1 71/4885OPRD1 207/4885OPRK1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.